Hand Eczema (HE)—Market Insights, Epidemiology, and Market Forecast—2032

Hand Eczema (HE)—Market Insights, Epidemiology, and Market Forecast—2032

DelveInsight’s ‘Hand Eczema (HE)—Market Insights, Epidemiology, and Market Forecast—2032’ report deliver an in-depth understanding of Hand Eczema (HE), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Hand Eczema (HE) market report provides current treatment practices, emerging drugs, and their market share of the individual therapies, current and forecasted Hand Eczema (HE) symptoms market size from 2019 to 2032 segmented by seven major markets. The report also covers current Hand Eczema (HE) symptoms treatment practice/algorithm and unmet medical needs to curate the best opportunities. It assesses the underlying potential of the market.

Geography Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019–2032

Hand Eczema (HE) Disease Understanding and Treatment Algorithm

Hand Eczema (HE) Overview

Hand Eczema (HE), also known as hand dermatitis, is one of the most common types of eczema and one of the most prevalent skin conditions worldwide. It mainly affects the palms but can also affect other parts of the hand. The severity of HE may range from very mild to severe and the course from acute to chronic, resulting in prolonged disability.

Hand Eczema (HE) Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnoses available in Hand Eczema (HE) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

DelveInsight’s Hand Eczema (HE) market report thoroughly understands Hand Eczema (HE) symptoms by including disease definition, symptoms, causes, physiology, and diagnosis. It also provides Hand Eczema (HE) treatment algorithms and treatment guidelines for Hand Eczema (HE) symptoms in the US, Europe, and Japan.

The current management of HE is nonspecific and commonly involves skin hydration, emollients, avoidance of irritants, and therapeutic intervention with topical corticosteroids (TCS) or systemic immunosuppressive therapies, such as short-term oral corticosteroids, and azathioprine, methotrexate, retinoids, and cyclosporine. The present market landscape of HE therapies is classified into four groups: topical corticosteroids, topical calcineurin inhibitors, UV therapy including PUVA, and others (Iontophoresis therapy, other topical therapies, salicylic acid, etc.).

Currently, the only medication approved to treat hand eczema patients is Toctino (alitretinoin). It is commercially available in many EU countries, Canada, and South Korea and is indicated for use in adults with severe CHE that is unresponsive to treatment with potent topical corticosteroids. However, it is not approved in the US and Japan.

A few major unmet needs in the market include the lack of disease-specific approved treatments, lack of clear understanding of disease pathogenesis, challenges in current management therapies, poor compliance with topical treatments, and the increasing prevalence are driving opportunities in the market.

Hand Eczema (HE) Epidemiology

Hand Eczema (HE) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends and assumptions.

Key Findings

The total prevalent cases of Hand Eczema (HE) patients in the 7MM are increasing during the study period, i.e., 2019–2032.

The disease epidemiology covered in the report provides historical as well as forecasted Hand Eczema (HE) symptoms epidemiology segmented as the total Prevalent cases of Hand Eczema, gender-specific cases of Hand Eczema, severity-specific cases of Hand Eczema, subgroup-specific cases of Hand Eczema, and age-specific cases of Hand Eczema. The report includes the prevalent cases scenario of Hand Eczema (HE) in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise Hand Eczema (HE) Epidemiology

The epidemiology segment also provides Hand Eczema (HE) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total number of prevalent cases of Hand Eczema (HE) associated in 7MM countries was around 63,300,000 in 2021.

Hand Eczema (HE) Drug Chapters

Hand Eczema (HE) report’s drug chapter segment encloses the detailed analysis of Hand Eczema (HE) early-stage (Phase II, and III) pipeline drugs. It also helps understand Hand Eczema (HE) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Hand Eczema (HE) Emerging Drugs

Dupilumab: Regeneron/Sanofi

Dupixent is a fully human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways. The Dupixent development program has shown significant clinical benefit and a decrease in type 2 inflammation in Phase III trials, establishing that IL-4 and IL-13 are key and central drivers of the type 2 inflammation that plays a major role in multiple related and often co-morbid diseases. These diseases include approved indications for Dupixent, such as asthma, atopic dermatitis, CRSwNP, and eosinophilic esophagitis, as well as investigational diseases such as prurigo nodularis. Dupixent is administered as an injection under the skin at different injection sites. Dupixent is intended for use under the guidance of a healthcare professional and can be given in a clinic or at home by self-administration after training by a healthcare professional. In children younger than 12 years of age, Dupixent should be administered by a caregiver if given at home. Dupixent does not require initial lab testing or ongoing lab monitoring.

The drug is currently in Phase III of clinical development for the treatment of moderate-to-severe hand eczema patients.

Delgocitinib: Leo Pharma/Japan Tobacco Inc.

Delgocitinib is an investigational, small-molecule, pan-Janus kinase (JAK) inhibitor blocking all four members of the JAK family (JAK1–3, tyrosine kinase 2). The JAK–STAT (signal transducer and activator of transcription protein) pathway plays a key role in the pathogenesis of many dermatological diseases. It also inhibits the activation of innate and adaptive immune cells, improves skin barrier function by modulating keratinocyte differentiation, inhibits T-helper (Th)1-, Th2-, Th17- and Th22-type inflammatory responses, and has antipruritic properties.

The drug is currently in Phase III of clinical development for the treatment of chronic hand eczema patients.

Other Products detailed in the report…

Hand Eczema (HE) Market Outlook

The report’s Hand Eczema (HE) market outlook helps to better understand the historic, current and forecasted Hand Eczema (HE) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of Hand Eczema (HE) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to view the market at first sight.

According to DelveInsight, Hand Eczema (HE) market in 7MM is expected to grow steadily during the study period 2019–2032.

Depending on the disease severity and chronicity, treatment includes topical and/or systemic corticosteroids to reduce inflammation and ceramide-containing moisturizers to repair the skin’s barrier function. Topical calcineurin inhibitors may be alternatives to topical corticosteroids. The most important step in managing HE is prevention with physical protective products (e.g., gloves) or barrier protection creams. Moreover, the disease management has to extend beyond mere pharmacological or physical treatment and requires an encompassing approach, including removal or avoidance of causative factors (skin irritants), behavioral changes, and social support.

Key Findings

This section includes a glimpse of Hand Eczema (HE) market in 7MM.

Hand Eczema (HE) market size in the seven major markets was around USD 11,000 million in 2021.

The United States Market Outlook

This section provides the total Hand Eczema (HE) market size and market size by therapies in the United States.

The United States accounts for the largest market size of Hand Eczema (HE) compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

EU-5 Countries: Market Outlook

The total Hand Eczema (HE) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

Japan Market Outlook

The total Hand Eczema (HE) market size and market size by therapies in Japan are also mentioned.

Hand Eczema (HE) Drugs Uptake

This section focuses on the uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers Hand Eczema (HE) market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps understand the drugs with the most rapid uptake, the reasons behind the maximal use of new drugs, and the comparison of the drugs based on market share and size, which will again be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Hand Eczema (HE) Pipeline Development Activities

The report provides insights into the therapeutic candidate in Phase I, II, and III stages. It also analyses Hand Eczema (HE) key players involved in developing targeted therapeutics.

Major market players include Regeneron, Incyte Corporation, Asana BioSciences, and others.

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions, mergers, licensing, and patent details for Hand Eczema (HE) emerging therapies.

In June 2014, Asana Biosciences was formed through the acquisition of the early-stage branded pharmaceutical discovery platform of Endo Pharmaceuticals, a subsidiary of Endo International plc. The deal of Endo International drug discovery portfolio includes an upfront payment as well as milestones on the achievement of certain development objectives.

Reimbursement Scenario in Hand Eczema (HE)

Proactively approaching reimbursement can induce a positive impact both during the early stages of product development and well after product launch. The report considers reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with better market access can be a critical business and price strategy.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in Hand Eczema (HE) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapies treatment patterns or Hand Eczema (HE) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of Hand Eczema (HE) Market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

• The report covers a descriptive overview of Hand Eczema (HE), explaining its causes, signs and symptoms, physiology, and currently available therapies.
• Comprehensive insight has been provided into Hand Eczema (HE) epidemiology and treatment in the 7MM.
• Additionally, an all-inclusive account of both the current and emerging therapies for Hand Eczema (HE) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
• A detailed review of Hand Eczema (HE) market, historical and forecasted, is included in the report, covering drug outreach in the 7MM.
• The report provides an edge while developing business strategies by understanding trends shaping and driving the global Hand Eczema (HE) market.

Report Highlights

• In the coming years, Hand Eczema (HE) market is set to change due to the rising awareness of the disease, the development of diagnostic techniques, and the favorable environment from regulators, for innovative first-in-class curative drugs, and are likely to expand the market’s size and enable the drug manufacturers to penetrate more into the market.
• The companies and academics are working to assess challenges and seek opportunities that could influence Hand Eczema (HE) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• Major players are involved in developing therapies for Hand Eczema (HE). The launch of emerging therapies will significantly impact Hand Eczema (HE) market.
• Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, and launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Hand Eczema (HE) Report Insights

• Patient Population
• Therapeutic Approaches
• Hand Eczema (HE) Pipeline Analysis
• Hand Eczema (HE) Market Size and Trends
• Market Opportunities
• Impact of upcoming Therapies

Hand Eczema (HE) Report Key Strengths

• 11 Years Forecast
• 7MM Coverage
• Hand Eczema (HE) Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Market
• Drugs Uptake

Hand Eczema (HE) Report Assessment

• Current Treatment Practices
• Unmet Needs
• Pipeline Product Profiles
• Market Attractiveness

Key Questions

Market Insights:

• What was Hand Eczema (HE) Market share (%) distribution in 2019, and how would it look in 2032?
• What would be Hand Eczema (HE) total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Hand Eczema (HE) market Size during the forecast period (2019–2032)?
• At what CAGR, Hand Eczema (HE) market is expected to grow in 7MM during the forecast period (2019–2032)?
• What would be Hand Eczema (HE) market outlook across the 7MM during the forecast period (2019–2032)?
• What would be Hand Eczema (HE) market growth till 2032, and what will be the resultant market Size in the year 2032?

Epidemiology Insights:

• What are the disease risk, burdens, and unmet needs of Hand Eczema (HE)?
• What is the historical Hand Eczema (HE) patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• What would be the forecasted patient pool of Hand Eczema (HE) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
• Out of all 7MM countries, which country would have the largest prevalent population of Hand Eczema (HE) during the forecast period (2019–2032)?
• At what CAGR is the population expected to grow in 7MM during the forecast period (2019–2032)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of Hand Eczema (HE) along with the approved therapy?
• What are the current treatment guidelines for treating Hand Eczema (HE) in the US, Europe, and Japan?
• What are the marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
• How many companies are developing therapies for the treatment of Hand Eczema (HE)?
• How many therapies are developed by each company for the treatment of Hand Eczema (HE)?
• How many emerging therapies are in the mid-stage and late stages of development to treat Hand Eczema (HE)?
• What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to Hand Eczema (HE) therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Hand Eczema (HE) and their status?
• What key designations have been granted for the emerging therapies for Hand Eczema (HE)?
• What are the global historical and forecasted markets for Hand Eczema (HE)?

Reasons to buy

• The report will help develop business strategies by understanding trends shaping and driving Hand Eczema (HE) market.
• To understand the future market competition in Hand Eczema (HE) market and an Insightful review of the key market drivers and barriers.
• Organize sales and marketing efforts by identifying the best opportunities for Hand Eczema (HE) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
• Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
• Organize sales and marketing efforts by identifying the best opportunities for Hand Eczema (HE) market.
• To understand the future market competition in Hand Eczema (HE) market.